Increasingly cardiac safety issues have arisen as a concern in the development of oncology medications. This session will focus on the potential safety issues of cardiotoxicity and QT prolongation and arrhythmogenesis and discuss their identification and potential management strategies. In addition, a state-of-the-art framework for collecting potential cardiac safety adverse events will be discussed and audience participation will be encouraged. The attendee will gain deeper theoretical and practical insight into the cardiac safety evaluation and risk-management of oncology medications during their development. This session is hosted by Cardiac Safety Research Consortium (CSRC)

Learning Objectives:
Describe the techniques to identify myocardial toxicity during the development of oncology medications
Identify the different approaches to assessing the potential for a development-stage oncologic compound to be arrhythmogenic and how to manage any potential risks
Explain how to proactively assess potential cardiac adverse events using a standardized methodology.